Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clariane SECHIX:CLARIP 56 Cash-to-Debt is 0.17 as of Jun. 2026, which is 55% above its 10-year median of 0.11. GuruFocus rates CHIX:CLARIP with a GF Score™ of 56/100 and a GF Value™ of €2.50 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 671 Healthcare Providers & Services companies, Clariane SE ranks worse than 76.9% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Clariane SE's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.17.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Clariane SEcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Clariane SE's Cash-to-Debt or its related term are showing as below:
CHIX:CLARIp'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05 Med: 0.11 Max: 0.18
Current: 0.17
During the past 13 years, Clariane SE's highest Cash to Debt Ratio was 0.18. The lowest was 0.05. And the median was 0.11.
CHIX:CLARIp's Cash-to-Debt is ranked worse than 76.9% of 671
companies
in the Healthcare Providers & Services industry
Industry Median: 0.8
vs CHIX:CLARIp: 0.17
Clariane SE (CHIX:CLARIp) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Clariane SE Cash-to-Debt Related Terms
Clariane SE Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Clariane SE's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:CLARIP vs HCA, THC, EHC: Cash-to-Debt Comparison
For the Medical Care Facilities subindustry, Clariane SE's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Clariane SE's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clariane SE (CHIX:CLARIP) has a Cash-to-Debt of 0.17 as of Jun. 2026. This is 55% above median its historical median of 0.11. Over the past decade, Clariane SE's Cash-to-Debt has ranged from 0.05 to 0.18. According to the industry distribution chart, Clariane SE ranks #516 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 76.9%.
Is Clariane SE's Cash-to-Debt too high?
Clariane SE's current Cash-to-Debt of 0.17 is 55% above median its 10-year median of 0.11. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.18. The Healthcare Providers & Services industry median Cash-to-Debt is 0.80. Clariane SE's value of 0.17 is 78.8% below this industry median. Based on the distribution chart, Clariane SE ranks #516 out of 671 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Clariane SE has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's Cash-to-Debt compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #516 out of 671 companies for Cash-to-Debt. This places Clariane SE in the lower half of its industry. The industry median Cash-to-Debt is 0.80. Clariane SE's value of 0.17 is 78.8% below this benchmark. Historically, Clariane SE's own Cash-to-Debt has ranged from 0.05 to 0.18 over the past decade. While the company's 10-year median is 0.11 vs. the industry median of 0.80, Clariane SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.80, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current Cash-to-Debt of 0.17 is 78.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current Cash-to-Debt is 0.17, which is 55% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.50, compared to a current price of €3.89 — trading 55.5% above its estimated fair value. The current Cash-to-Debt is 0.17, which is 55% above median its 10-year median of 0.11 and 78.8% below the Healthcare Providers & Services industry median of 0.80. Clariane SE's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current Cash-to-Debt is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €3.89 is trading 55.5% above its estimated GF Value™ of €2.50.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for CHIX:CLARIP:
Cash-to-Debt: 0.17 (55% above median its 10-year median of 0.11)
GF Value™: €2.50 vs. price of €3.89 (55.5% above fair value)
Industry Position: 78.8% below the Healthcare Providers & Services median (#516 of 671)
No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
56GF Score
Get the complete analysis for CHIX:CLARIP
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CLARIP has been successfully added to your 
